However, subgroup analyses of the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. Aspirin to Prevent Embolism in Embolic Strokes of Undetermined Sources (NAVIGATE ESUS) trial found that while CMB are a marker of increased risk of recurrent stroke and mortality, they do not increase the risk of poor outcomes for patients on rivaroxaban vs. aspirin, which is encouraging (35). The gene discussed is F10; the disease is stroke disorder.